Clinically Relevant Models
Living & diverse bank of clinically relevant models that correlate with clinical outcomes
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses
Renal Cell Carcinoma PDX models & Kidney Cancer PDX Models
Champions Oncology offers 29* clinically relevant Renal Cell Carcinoma PDX models & Kidney Cancer PDX Models models derived from patients with late-stage, metastatic, and heavily pre-treated disease, providing a rare and valuable resource for oncology drug development. Many of these models are extensively characterized through Next Generation Sequencing—36* with Whole Exome Sequencing (WES), 27* with RNA-seq, and 27* with both—along with in vivo drug response data, enabling robust biomarker analysis for response and non-response within this indication. More details on these models can be accessed via Champions’ Model Select®.
(*Model numbers fluctuate as our dataset continuously evolves.)
Champions' leading Renal Cell Carcinoma PDX models & Kidney Cancer PDX Model cohort showcases primary models, each reflecting key clinical characteristics, mutations, and pretreatment history.
-
Access to one of the largest bank of Renal Cell Carcinoma & Kidney Cancer PDX models with clinically relevant molecular and pathological characteristics on the market.
-
Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics and Phosphoproteomics.
-
Includes models pretreated with an array of advanced treatments, from monoclonal antibodies to targeted inhibitors in combination.